Travere Therapeutics is a biopharmaceutical company dedicated to transforming the lives of those affected by rare diseases. Their mission is to identify, develop, and deliver groundbreaking therapies that have the potential to change lives. With a focus on rare kidney and metabolic diseases, they are driven by scientific innovation and are committed to setting new standards of care in these fields.

As a company, Travere Therapeutics places a strong emphasis on patient advocacy, diversity, equality, and inclusion. They believe in providing a sense of belonging and support to those in need. Through their grant programs, they actively contribute to the advancement of research and education in rare diseases.

Travere Therapeutics' pipeline includes promising treatments for various rare conditions such as IgA nephropathy, focal segmental glomerulosclerosis, and Alagille Syndrome. Through their dedication to scientific progress and their commitment to patients, Travere Therapeutics is making a profound impact on the lives of individuals living with rare diseases